| __timestamp | Corcept Therapeutics Incorporated | Perrigo Company plc |
|---|---|---|
| Wednesday, January 1, 2014 | 34916000 | 675200000 |
| Thursday, January 1, 2015 | 36949000 | 771800000 |
| Friday, January 1, 2016 | 45240000 | 1205500000 |
| Sunday, January 1, 2017 | 62416000 | 1146500000 |
| Monday, January 1, 2018 | 81289000 | 1125800000 |
| Tuesday, January 1, 2019 | 100359000 | 1166100000 |
| Wednesday, January 1, 2020 | 105326000 | 1175500000 |
| Friday, January 1, 2021 | 122356000 | 1111400000 |
| Saturday, January 1, 2022 | 152848000 | 1210100000 |
| Sunday, January 1, 2023 | 184259000 | 1274600000 |
Data in motion
In the ever-evolving pharmaceutical landscape, understanding the financial strategies of key players is crucial. Over the past decade, Corcept Therapeutics Incorporated and Perrigo Company plc have demonstrated distinct patterns in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Corcept's SG&A expenses surged by over 400%, reflecting a strategic investment in growth and market expansion. In contrast, Perrigo's SG&A expenses increased by approximately 89%, indicating a more stable approach to operational spending.
Corcept's aggressive spending, peaking at nearly $184 million in 2023, underscores its commitment to scaling operations and enhancing market presence. Meanwhile, Perrigo's consistent expenditure, reaching about $1.27 billion in the same year, highlights its focus on maintaining a robust market position. These trends offer valuable insights into the companies' strategic priorities and their impact on the competitive dynamics of the pharmaceutical industry.
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Corcept Therapeutics Incorporated Trends and Insights
Alnylam Pharmaceuticals, Inc. vs Corcept Therapeutics Incorporated: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for United Therapeutics Corporation and Perrigo Company plc
Insmed Incorporated and Corcept Therapeutics Incorporated: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Corcept Therapeutics Incorporated and Rhythm Pharmaceuticals, Inc.
Corcept Therapeutics Incorporated vs Bausch Health Companies Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Corcept Therapeutics Incorporated and Iovance Biotherapeutics, Inc.
Comparing SG&A Expenses: Corcept Therapeutics Incorporated vs BioCryst Pharmaceuticals, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Ionis Pharmaceuticals, Inc. and Perrigo Company plc
Comparing SG&A Expenses: Ultragenyx Pharmaceutical Inc. vs Perrigo Company plc Trends and Insights
SG&A Efficiency Analysis: Comparing Perrigo Company plc and Vericel Corporation
Cost Management Insights: SG&A Expenses for Perrigo Company plc and Mesoblast Limited